Loading color scheme

News & Resources

09 November 2021

OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients. ONC-392 is the only clinically tested nextgen anti-CTLA-4 monoclonal antibody that through a unique mechanism recycles, instead of destroys, the CTLA-4 molecules thereby reducing immunotherapy-related toxicity induced by the CTLA-4 depletion while enhancing therapeutic activities.

Read more
27 May 2021

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership

SHANGHAI and ROCKVILLE, Md.May 26, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.

Read more
23 November 2020

Merck to Acquire OncoImmune

KENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.

Read more
23 September 2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020.

Read more
30 December 2019

OncoImmune Announces Approval of IND Application for ONC-392 The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy

OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration (“FDA”). The IND approval enables OncoImmune to begin a Phase 1A/1B clinical trial of ONC-392 that is designed to assess the safety, pharmacokinetics, and efficacy of ONC-392 as a single agent in advanced solid tumors and in combination with anti-PD(L)1 standard of care in Non- Small Cell Lung Cancer. This open label trial is expected to begin in early 2020.

Read more